We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

195 hedge funds and large institutions have $2.37B invested in BridgeBio Pharma in 2021 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 72 increasing their positions, 65 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more call options, than puts

Call options by funds: $122M | Put options by funds: $72.8M

11% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 65

3.03% more ownership

Funds ownership: 93.48% → 96.51% (+3%)

7% less funds holding

Funds holding: 210 → 195 (-15)

27% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 51

64% less capital invested

Capital invested by funds: $6.56B → $2.37B (-$4.19B)

67% less funds holding in top 10

Funds holding in top 10: 15 → 5 (-10)

Holders
195
Holders Change
-15
Holders Change %
-7.14%
% of All Funds
3%
Holding in Top 10
5
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-66.67%
% of All Funds
0.08%
New
37
Increased
72
Reduced
65
Closed
51
Calls
$122M
Puts
$72.8M
Net Calls
+$49M
Net Calls Change
+$54.4M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$53.3M
2
OCA
Octagon Capital Advisors
New York
+$50.7M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$47.4M
4
Citigroup
Citigroup
New York
+$31.1M
5
AIMCA
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
+$29.6M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$111M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$37.3M
3
BlackRock
BlackRock
New York
-$36.6M
4
PA
Perceptive Advisors
New York
-$26.6M
5
BAMCO Inc
BAMCO Inc
New York
-$22.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
CM
226
Capula Management
Cayman Islands
– -$244K -5,216 Closed
X
227
Xponance
Pennsylvania
– -$237K -5,053 Closed
OSAM
228
O'Shaughnessy Asset Management
Connecticut
– -$180K -3,829 Closed
PCM
229
Penserra Capital Management
California
– -$160K -3,425 Closed
MAM
230
Meeder Asset Management
Ohio
– -$95K -2,034 Closed
First Manhattan
231
First Manhattan
New York
– -$18K -400 Closed
EW
232
Evoke Wealth
California
– -$15K -330 Closed
LFG
233
Larson Financial Group
Missouri
– -$12K -253 Closed
TWA
234
TCI Wealth Advisors
Arizona
– -$7K -151 Closed
BIA
235
Bell Investment Advisors
California
– -$4.87K -115 -90%
GRP
236
Global Retirement Partners
California
– -$5K -100 Closed
EWA
237
Evolution Wealth Advisors
Florida
– -$3K -68 Closed
IFAM
238
Institutional & Family Asset Management
Colorado
– -$296 -7 -54%
SC
239
Schubert & Co
Texas
– +$85 +2 New
Carson Wealth (CWM LLC)
240
Carson Wealth (CWM LLC)
Nebraska
– +$635 +15 New
SCA
241
Snowden Capital Advisors
New York
– +$804 +19 New
JWA
242
JFS Wealth Advisors
Pennsylvania
– +$1.06K +25 New
6 7 8 9
10

BBIO Hedge Fund Activity: Q4 2021 in Review

195 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2021, worth a combined $2.37B — down 64% from $6.56B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of BBIO and 37 opened new positions — a net loss of 14 holders — while 65 trimmed existing stakes and 72 added.

The largest buyer was Millennium Management, adding an estimated $53.3M. The largest seller was Janus Henderson Group, cutting an estimated $111M.

  • 195 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2021, down from 210 in Q3 2021.
  • Funds reported $2.37B of BridgeBio Pharma stock for Q4 2021, down 64% quarter-over-quarter.
  • 37 funds opened new BridgeBio Pharma positions in Q4 2021 and 51 closed out, a net change of -14 holders.
  • The largest BridgeBio Pharma buyer in Q4 2021 was Millennium Management, an estimated $53.3M added.
  • The largest BridgeBio Pharma seller in Q4 2021 was Janus Henderson Group, an estimated $111M sold.

Based on aggregated 13F filings for Q4 2021.